Richmond pharmaceutical company Phlow Corp. recently completed a $36 million Series B round that it will use to grow its commercial and manufacturing businesses.
The company did not divulge the names of the participants in the round, but said it included new and existing investors.
“The Series B raise is a great testament to the progress we have made,” Phlow President Dan Hackman said. “It allows us to make great progress in the coming years.”
Phlow, a public benefit corporation, was…
